Riskpilot← Back to searchSign inGet full accessJJ PHARMA CONSULT ApS
APSActiveCVR 33257635Rosenørns Allé 16, 2.Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2010— employees
Revenue 2025
DKK -79K
+47% vs 2024
EBITDA margin
100.0%
-44% vs 2024
Equity ratio
99.7%
Financial strength
Net profit 2025
DKK -1,2M
-194% vs 2024
| Revenue | DKK -79K | +47% |
| EBITDA | DKK -79K | -44% |
| Net profit | DKK -1,2M | -194% |
| Total assets | DKK 17M | -13% |
| Equity | DKK 16,9M | -11% |
| Employees | — | — |
Legal name
JJ PHARMA CONSULT ApS
CVR number
33257635
Legal form
Anpartsselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
1. november 2010
Share capital
DKK 80.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 1 direktør.
Company purpose
Selskabets formål er at drive erhvervsvirksomhed med handel og at fungere som holdingselskab ved at eje kapitalinteresser i andre virksomheder.
Address
Rosenørns Allé 16, 2.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -6 | -9 | -23 | -17 | -45 | -18 | -40 | -22 | -20 | -14 | -19 | -13 | -54 | -79 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -6 | -9 | -23 | -17 | -45 | -18 | -40 | -22 | -20 | -2.143 | -19 | -13 | -55 | -79 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -6 | -9 | -23 | -17 | -45 | -18 | -40 | -22 | -20 | -2.143 | -19 | -13 | -55 | -79 |
| Net financials | 29 | 103 | 943 | 600 | 360 | 603 | -2 | -5 | 1.030 | 1.557 | 499 | 17.611 | 1.678 | -1.016 |
| Profit before tax | 22 | 95 | 920 | 582 | 315 | 585 | -43 | -27 | 1.010 | -587 | 480 | 17.598 | 1.624 | -1.095 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 6 | -0 | 110 | 363 | 94 |
| Net profit | 22 | 95 | 920 | 582 | 315 | 585 | -43 | -27 | 1.010 | -593 | 480 | 17.488 | 1.260 | -1.189 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 606 | 568 | 948 | 1.433 | 1.647 | 2.128 | 1.980 | 1.841 | 2.741 | 2.035 | 2.371 | 18.969 | 19.492 | 16.965 |
| Equity | 89 | 183 | 934 | 1.416 | 1.630 | 2.112 | 1.964 | 1.828 | 2.697 | 1.991 | 2.358 | 18.846 | 19.106 | 16.917 |
| Long-term debt | 295 | 153 | 11 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 222 | 231 | 14 | 16 | 16 | 16 | 16 | 13 | 44 | 44 | 13 | 123 | 385 | 48 |
| Total debt | 517 | 384 | 14 | 16 | 16 | 16 | 16 | 13 | 44 | 44 | 13 | 123 | 385 | 48 |
EBITDA margin
-7908800.0%
This company
15.8%
Market median
-50055796% vs market
20122025
Equity ratio
99.7%
This company
38.2%
Market median
+161% vs market
20122025
Return on equity
-7.0%
This company
18.4%
Market median
-138% vs market
20122025
Net profit margin
-118906400.0%
This company
8.1%
Market median
-1467980347% vs market
20122025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2010 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of JJ PHARMA CONSULT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|